Capitala Group and Pike Street Capital Invest $19.5M in US BioTek Laboratories
January 8, 2019
Capitala Group, alongside Pike Street Capital, provided a $19.5 million financing package (senior secured debt and equity) to US BioTek Laboratories to support the company's next phase of growth. The capital will fund expansion of US BioTek's specialty immunology and allergy testing capabilities as well as sales and marketing initiatives.
- Buyers
- Capitala Group, Pike Street Capital
- Targets
- US BioTek Laboratories LLC
- Industry
- Healthcare Services
- Location
- Washington, United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Merck KGaA to Acquire Bio-Techne for $11.3 Billion
June 25, 2026
Healthcare Services
Merck KGaA has entered a definitive agreement to acquire Bio-Techne for $73 per share in an all-cash transaction valued at about $11.3 billion (enterprise value). The deal is expected to close in late 2026 or early 2027, subject to regulatory approvals and Bio-Techne shareholder approval.
-
US BioTek Laboratories Merges With NutriPATH Pathology
March 3, 2026
Healthcare Services
US BioTek Laboratories, a Seattle-based functional laboratory, has completed a strategic merger with Australian functional pathology provider NutriPATH Pathology based in Melbourne. The combined organization expands functional pathology and diagnostic testing capabilities and extends international access for healthcare providers, while NutriPATH continues operating under its established brand in Australia.
-
US BioTek Laboratories Acquires RealTime Laboratories
March 19, 2024
Healthcare Services
US BioTek Laboratories, a Pike Street Capital portfolio company, has acquired Dallas-based RealTime Laboratories to expand its diagnostic testing capabilities, specifically mycotoxin and infectious disease testing. The deal broadens the combined organization’s services and geographic footprint while both labs continue operating at their respective locations.
-
Align Capital Partners Recapitalizes Premier Biotech
December 7, 2022
Medical Devices
Align Capital Partners has completed a recapitalization of Premier Biotech, a Minneapolis-based provider of point-of-care drugs of abuse testing devices and accredited laboratory services. Cascadia Capital served as exclusive financial advisor; Align will partner with management to scale the business, accelerate product development and expand the company's reach across workplace, government and clinical end markets.
-
Pike Street Capital Invests in PumpTech
September 13, 2021
Industrial Services
Seattle-based private equity firm Pike Street Capital has made an investment in PumpTech, a Bellevue, Washington-based distributor of pumps and related services founded in 1986. Pike Street has partnered with industry executive Doug Staab to grow PumpTech as a platform through add-on acquisitions to expand product lines, service capabilities, and geographic reach; the company founders will remain significant investors and in leadership roles.
-
TPG Capital and Vida Ventures Invest $225M in Asklepios BioPharmaceutical (AskBio)
April 11, 2019
Biotechnology
Asklepios BioPharmaceutical (AskBio) raised $235 million in new capital, with TPG Capital and Vida Ventures investing $225 million for a minority stake while AskBio’s founders and board co-invested $10 million. The funding will be used to accelerate clinical development and expand manufacturing capabilities, particularly for AskBio’s AAV gene therapy platform and pipeline.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.